TCT
The Take Home: TCT
This year, Transcatheter Cardiovascular Therapeutics was held as a hybrid meeting Nov. 4 to 6, with some participants attending in person in Orlando and others attending virtually.
Top news of TCT 2021: CABG vs. FFR-guided PCI, LAA closure devices and more
Healio and Cardiology Today have curated a list of the most-read headlines from TCT 2021.
Closure systems for TAVR procedures vary by complications, time to hemostasis
In a trial of vascular closure systems in patients who had transcatheter aortic valve replacement, a plug-based system was associated with more vascular complications but shorter time to hemostasis compared with a suture-based system.
Post-PCI, clopidogrel monotherapy after 1 month reduces bleeding risk vs. 12-month DAPT
In a pooled cohort of the two STOPDAPT-2 trials, among patients who underwent PCI, switching from dual antiplatelet therapy to clopidogrel monotherapy after 1 month reduced bleeding risk compared with 12-month DAPT.
Magnetically controlled capsule endoscopy detects GI injury from antiplatelet therapy
Magnetically controlled capsule endoscopy identified gastrointestinal injury in a majority patients taking antiplatelet therapies following PCI and may represent a noninvasive alternative to standard upper GI endoscopy, a speaker reported.
GUIDE-HF: Benefit of hemodynamic guided-management in HF similar across EF
Device therapy for pulmonary artery-pressure-guided management of patients with HF was beneficial regardless of ejection fraction, according to new data from the GUIDE-HF trial presented at TCT 2021.
Transcatheter mitral valve replacement may benefit patients with mitral regurgitation
At 30 days, a group of 15 patients who underwent transfemoral transcatheter mitral valve replacement for moderate to severe mitral regurgitation had no deaths, strokes, reinterventions or new pacemakers, a speaker reported.
Abbreviated DAPT beneficial after PCI in high-risk patients regardless of MI status
In a subgroup analysis of MASTER-DAPT, regardless of whether patients had a history of MI, 1-month DAPT after PCI was noninferior to 3-month or longer DAPT for ischemic events and conferred a reduction in bleeding events.
Head-to-head trial of LAA closure devices yields mixed results: SWISS-APERO
In a head-to-head trial of the Amplatzer Amulet and Watchman FLX left atrial appendage closure devices, the primary endpoint of crossover to the other device or residual LAA patency at 45 days was similar, researchers reported at TCT 2021.
LAA closure remains noninferior to direct oral anticoagulants over long term
Among patients with atrial fibrillation at high risk for stroke, left atrial appendage closure remained noninferior to direct oral anticoagulation for preventing major CV and neurological events out to 4 years.